Investment Rating - The report maintains a "Buy" rating on the overseas education sector, specifically highlighting China Oriental Education as a key investment target [1]. Core Insights - The report indicates a positive outlook for vocational education training, with operational efficiency continuously improving. China Oriental Education is expected to achieve a net profit growth of 46% to 51% in 2025, with adjusted net profit projected between 767 million to 793 million RMB [1][7]. - The vocational training market is anticipated to benefit from an increase in high school graduates who do not enter university, leading to a significant rise in demand for vocational skills training [2][8]. - The company is implementing refined management strategies to enhance operational efficiency, expecting a gross margin increase of 5.2 percentage points to 56.5% in 2025 [3][9]. - Capital expenditures are projected to decline, with a forecast of approximately 660 million RMB in 2025, a decrease of 33.6% year-on-year, while maintaining a high dividend payout ratio [4][10]. Summary by Sections Market Overview - The education index fell by 3.2% in the week of February 6-12, underperforming the Hang Seng Index by 4.1 percentage points. Year-to-date, the education index has risen by 12.86%, outperforming the Hang Seng Index by 9.93 percentage points [6]. Company Updates - China Oriental Education has released a positive profit forecast for 2025, with an expected net profit growth of 46% to 51%, translating to an adjusted net profit of 767 million to 793 million RMB. The company anticipates a 6% increase in new training participants, driving revenue growth to between 12% and 46.1 billion RMB [7][8]. Vocational Training Demand - The vocational training sector is set to experience growth due to a mismatch in university enrollment rates and an increase in high school graduates. The number of high school graduates has risen by 2.6 million from 2021 to 2024, while university enrollment has only increased by 320,000 during the same period [2][8]. Operational Efficiency - The company is expected to continue its lean management approach from 2024, coordinating recruitment across schools to improve capacity utilization. The marketing expense ratio is projected to decrease by 2.5 percentage points to 21.2% in 2025, contributing to a net profit margin increase of 4.4 percentage points to 17.2% [3][9]. Capital Expenditure and Dividends - The company has initiated a vocational education center construction plan, with five out of six centers expected to be completed between 2023 and 2025. The capital expenditure for 2025 is estimated at 660 million RMB, with a high dividend payout ratio suggesting a dividend yield of 5.6% [4][10]. Investment Recommendations - The report recommends focusing on Hong Kong-listed vocational education companies, particularly China Oriental Education, due to its strong growth prospects and operational adjustments aimed at capturing the vocational training demand from high school graduates [13].

Group 1 - The core focus of the article is on the corporate governance of Lepu Biopharma-B (02157.HK), highlighting a proposed ten-year restricted share unit plan aimed at incentivizing and retaining employees [1] - The plan is set to be discussed at the second extraordinary general meeting scheduled for December 18, 2025 [1] - The maximum number of shares to be granted under this plan is capped at 5% of the total issued shares as of the adoption date [1]

Company Overview - The company, Vaimo Biotechnology (Zhejiang) Co., Ltd., focuses on the ophthalmology sector and aims to become a global leader in innovative ophthalmic therapies [4] - Established in 2016, the company has developed a competitive and differentiated product pipeline addressing various ophthalmic indications with significant unmet clinical needs [4] Core Products - VVN461 (High Dose) is a novel dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), currently undergoing Phase III clinical trials in China for non-infectious anterior uveitis (NIAU) [4][6] - VVN001 is a second-generation LFA-1 antagonist designed for treating dry eye disease (DED), with ongoing Phase III clinical trials in China [4][9] Clinical Development - VVN461 has shown comparable anti-inflammatory efficacy to corticosteroids in head-to-head Phase II trials, with a breakthrough therapy designation granted by the National Medical Products Administration (NMPA) [7] - VVN001 demonstrated higher efficacy and safety compared to the standard treatment cyclosporine A (CsA) in clinical trials, improving patient experience and compliance [10] Financial Information - For the nine months ending September 30, 2024, the company reported other income and gains of approximately RMB 8.572 million, with research and development expenses of about RMB 128.261 million [11] - The company incurred losses of approximately RMB 201.535 million for the fiscal year ending 2024 [12] Industry Overview - The global ophthalmic drug market is estimated to reach USD 41.6 billion in 2024, with a projected compound annual growth rate (CAGR) of 2.8% from 2024 to 2029, driven by an aging population and increasing prevalence of eye diseases [13] - The Chinese ophthalmic drug market is expected to grow from USD 2.7 billion in 2020 to USD 4.1 billion in 2024, with a CAGR of 10.8% [16]

以上内容基于公开资料整理，不构成投资建议。 昊海生科 昊海生物科技 分时图 日K线 周K线 月K线 46.13 -0.34 -0.73% 0.77% 0.52% 0.26% 0.00% 0.26% 0.52% 0.77% 46.11 46.23 46.35 46.47 46.59 46.71 46.83 09:30 10:30 11:30/13:00 14:00 15:00 15:30 0 8152 2万 2万 经济观察网2026年2月12日，昊海生科发布公告称，股东楼国梁因自身资金需要，计划通过集中竞价和 大宗交易方式减持不超过100万股公司股份，占公司总股本的比例不超过0.4337%。截至公告日，楼国 梁持有公司股份约712万股，持股比例为3.0882%。该减持计划自公告披露后3个交易日起的3个月内实 施，可能对短期市场情绪构成压力。 股票近期走势 受股东减持公告影响，昊海生科股价近期表现偏弱。截至2026年2月13日开盘，股价报46.47元，近5日 累计下跌1.09%。2月12日单日下跌0.81%，成交额约1978.85万元，主力资金净流出6.53万元，显示短期 资金面承压。同期，医药生物板块整体微跌0 ...

Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating potential investor concerns and market volatility [1] - On February 12, Junshi Biosciences' stock fell by 1.23%, with a trading volume of 243 million yuan, and a net financing outflow of approximately 14.89 million yuan [1] - As of February 12, the total margin balance for Junshi Biosciences was 1.423 billion yuan, with a financing balance of 1.412 billion yuan, representing 5.33% of the circulating market value, which is above the 90th percentile of the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% increase [2] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]

Company Overview - The company, established in 2016, focuses on the ophthalmology sector and aims to become a global leader in innovative ophthalmic therapies [5] - It has developed a competitive and differentiated product pipeline addressing various ophthalmic indications with significant unmet clinical needs [5] Core Products - VVN461 (high dose) is a novel dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), currently undergoing Phase III clinical trials in China for non-infectious anterior uveitis (NIAU) [5][6][8] - VVN001 is a second-generation LFA-1 antagonist designed for treating dry eye disease (DED), with ongoing Phase III clinical trials in China [10][11] Clinical Trials and Approvals - VVN461 received IND approval from the National Medical Products Administration (NMPA) in January 2023 and has shown comparable anti-inflammatory efficacy to corticosteroids in clinical trials [8][7] - VVN001 has also received IND approval and has demonstrated higher efficacy and safety compared to the standard treatment, cyclosporine A [11][10] Financial Information - The company reported other income and gains of RMB 8.572 million and RMB 3.444 million for the nine months ending September 30 in 2024 and 2025, respectively [12][14] - Research and development expenses were approximately RMB 128.261 million and RMB 65.178 million for the same periods, with annual losses of RMB 201.535 million and RMB 131.495 million [13][14] Industry Overview - The global ophthalmic drug market is estimated to reach USD 41.6 billion in 2024, with a projected CAGR of 2.8% from 2024 to 2029, driven by an aging population and increasing prevalence of eye diseases [15][18] - The Chinese ophthalmic drug market is expected to grow from USD 2.7 billion in 2020 to USD 4.1 billion in 2024, with a CAGR of 10.8%, and further growth anticipated to USD 6.6 billion by 2029 [18]

机构观点 营收增长主要依赖核心产品艾可宁及新业务，但增速已降至个位数。净利润亏损同比增亏，主要因2024 年处置子公司收益缺失；研发费用投入1.38亿元至1.45亿元，同比微增，聚焦小核酸药物管线。公司坦 言新药研发周期长、风险高。 股票近期走势 近期股价波动明显，近5日下跌0.82%，反映市场对公司业绩及研发风险的谨慎情绪。 经济观察网前沿生物发布2025年业绩预告，预计营收1.4亿元至1.45亿元，同比增长8.13%至11.99%，增 速持续下滑；归属净利润亏损扩大至2.55亿元至2.9亿元。公司研发重心转向小核酸药物，多款产品处于 早期阶段。 财报分析 分析指出，公司核心产品放量受行业免费药物格局制约，小核酸药物虽为长期增长点，但均处临床前或 早期阶段，未来面临审批、竞争等多重风险。公司需突破盈利瓶颈。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - Tyligand Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, planning to list on the Hong Kong Stock Exchange under the 18A rule with a primary focus on small molecule drugs and ADC candidates [1][3]. Financial Performance - The company reported revenues of approximately RMB 0.08 billion for 2024 and RMB 0.11 billion for the first nine months of 2025, reflecting a year-on-year increase of 654.18% [4]. - The net losses were RMB 0.70 billion in 2024 and RMB 1.23 billion in the first nine months of 2025, with a year-on-year increase of 335.23% [4]. - Gross margins were reported at 90.64% for 2024 and 78.31% for the first nine months of 2025 [4]. - Research and development expenses were RMB -0.73 billion for 2024 and RMB -0.91 billion for the first nine months of 2025, with a year-on-year increase of 80.62% [4]. Drug Development Pipeline - The company has a drug portfolio that includes four candidates, with TSN1611 being the core product currently in Phase 2 clinical trials in the US and China for non-small cell lung cancer (NSCLC) [1][3]. - TSN1611 is a highly selective oral KRAS G12D inhibitor, with plans for a pivotal registration trial in China [1]. Industry Overview - The global market for KRAS G12D inhibitors is projected to grow from USD 81.8 million in 2027 to USD 3,481.6 million by 2035, with a compound annual growth rate (CAGR) of 59.8% [8]. - The Chinese market for KRAS G12D inhibitors is expected to increase from USD 12.3 million in 2027 to USD 446.5 million by 2035, with a CAGR of 56.7% [8][9]. Competitor Analysis - Comparable companies in the industry include Jinfang Pharmaceutical-B, Hengrui Medicine, and Revolution Medicines, with varying IPO details and financial metrics [12]. - Tyligand Biosciences has a current gross margin of 90.64%, which is competitive within the industry [12]. Management and Shareholding Structure - The board of directors consists of five members, including two executive directors and three non-executive directors [13]. - Major shareholders include Tyligand Holdings, which holds 23.66% of the company, with significant stakes from other investors such as Tencent and Kangzhe Pharmaceutical [15]. Financing History - The company has undergone multiple rounds of financing, with the latest B round valuing the company at approximately USD 222.2 million [17].

Summary of Conference Call for Reborio Biotech Company and Industry - **Company**: Reborio Biotech (瑞博生物) - **Industry**: MASH (Metabolic Associated Steatotic Hepatitis) treatment and small nucleic acid therapeutics Key Points and Arguments 1. **Collaboration with Madrigal**: Reborio has entered into a business development agreement with Madrigal (MDGL), which includes a $60 million upfront payment and potential milestones totaling $4.3 billion. This partnership is seen as mutually beneficial, particularly in the large market for MASH indications [1] 2. **Reborio's Expertise**: Reborio possesses significant experience in transitioning from preclinical to clinical stages, which aligns well with the clinical requirements outlined by MDGL. This capability allows Reborio to accurately determine preclinical data needs, facilitating the collaboration [1] 3. **Madrigal's Position**: Madrigal is recognized as a pioneer in the MASH field, with its product Rezdiffra being a daily oral treatment. The acquisition of Pfizer's DGAT2 has positioned Madrigal favorably, with no other companies currently entering the MASH space [2] 4. **Combination of Therapies**: The collaboration aims to combine Madrigal's short-acting small molecules with Reborio's long-acting small nucleic acids, creating a synergistic treatment approach [2] 5. **Unmet Clinical Needs**: There is a significant unmet clinical need in MASH, as existing drug mechanisms are too generic. Current treatments primarily reduce liver fat, indirectly addressing disease impact without targeting disease characteristics, fibrosis, or specific genotypes and subtypes [2] 6. **Reborio's Focus**: Although Reborio has excellent preclinical data for MASH, it is not the primary focus of the company’s clinical strategy. The optimal solution is to pursue licensing agreements rather than direct clinical development [2] 7. **Pipeline Diversity**: The collaboration encompasses six distinct pipelines that offer complementary mechanisms, indicating a strategic approach to diversifying treatment options [2] 8. **Future Milestones**: Within the next two years, Reborio aims to achieve at least one Investigational New Drug (IND) application for MASH or generate significant revenue [2] 9. **Collaboration with Boehringer Ingelheim (BI)**: Reborio's collaboration with BI focuses on different targets and indications compared to MDGL, with BI emphasizing late-stage liver disease and complications, aiming for scientific breakthroughs in first-in-class (FIC) innovations [2] 10. **Progress and Milestones**: Current progress aligns with expectations, having already achieved two milestones, with the anticipated timeline for the MDGL collaboration pipeline to enter IND status concurrently [2] 11. **Innovative Technologies**: Reborio is leading globally in kidney-targeted therapies and has early-stage assets for liver-external delivery, as well as dual-target approaches [2]

Company and Industry Summary Company: WuXi Biologics Key Points - **High Growth in Dual Antibody and ADC**: WuXi Biologics is experiencing rapid growth in dual antibodies (双多抗) and antibody-drug conjugates (ADC), with a significant market share that positions the company to potentially outperform in new molecular tracks [1][1] - **Revenue Contribution**: Dual antibodies currently contribute nearly 20% of the group's revenue, with a year-on-year growth exceeding 120% [1][1] - **Project Pipeline**: In 2025, two-thirds of the new projects signed by the company will be in dual antibodies and ADC, with approximately half of these projects originating from the United States [1][1] - **ADC Projects**: The company has a total of 252 ADC projects, indicating a sustained upward trend in market conditions for this segment [1][1] - **Market Share in Dual Antibodies**: WuXi Biologics holds a market share of over 55% in the dual antibody domain, with expectations for the M-end to release growth potential as project conversion progresses [1][1] - **Record Project Numbers**: The company is set to achieve a record number of projects in 2025, with a significant increase in PPQ (Process Performance Qualification) projects [1][1] - **Total Projects**: By the end of 2025, the total number of projects is expected to reach 945, including 74 in Phase 3 clinical trials and 25 commercial projects [1][1] - **PPQ Projects Timeline**: The company plans to complete 28 PPQ projects in 2025 and has scheduled 34 PPQ projects for 2026, indicating a continuous increase in project activity [2][2] - **Commercialization Timeline**: It is estimated that it takes about two years from PPQ to commercial production, with the M-end's commercialization potential expected to accelerate post-2027 [2][2] - **Revenue and Profit Forecast**: Projected revenues for 2025, 2026, and 2027 are estimated at 21.79 billion, 25.92 billion, and 31.02 billion yuan respectively, with adjusted net profits of 5.71 billion, 6.94 billion, and 8.49 billion yuan [2][2] - **Valuation Metrics**: Corresponding valuations based on current market capitalization are projected to be 28x, 23x, and 19x for the years 2025, 2026, and 2027 respectively [2][2] Risk Factors - **Geopolitical Risks**: The company faces potential geopolitical risks that could impact operations and market performance [3][3] - **Sales Performance Risks**: There is a risk that the sales of commercialized products may not meet expectations [3][3]